Cancer Advances Overview

  • Founded
  • 2008
  • Status
  • Private
  • Employees
  • 2
  • Latest Deal Type
  • Buyout/​LBO
  • Investors
  • 1

Cancer Advances General Information


Developer of oncology drugs designed to improve the quality of life and to extend the survival of patients with gastrointestinal cancers. The company's drug Polyclonal Antibody Stimulator (PAS), is an immunomodulator that blocks the function of gastrin and slows down tumor growth, the incidence of metastasis, and also changes the tumor micro environment, enabling physicians to improve medical outcomes and improve the lives of their patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Westpark Corporate Center
  • 4364 South Alston Avenue, Suite 210
  • Durham, NC 27713
  • United States
+1 (919) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cancer Advances Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Buyout/LBO Completed Startup
To view Cancer Advances’s complete valuation and funding history, request access »

Cancer Advances Executive Team (4)

Name Title Board Seat Contact Info
John Wingen Chief Financial Officer
Allen Cato MD Co-Founder, Chief Executive Officer & Chief Medical Officer
Lynda Sutton President
You’re viewing 3 of 4 executive team members. Get the full list »

Cancer Advances Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cancer Advances Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cato BioVentures Corporate Venture Capital Majority 000 0000 000000 0
To view Cancer Advances’s complete investors history, request access »